News

Administered as a once-daily single injection independently of meals, Xultophy is a combination of basal insulin Tresiba (insulin degludec) and GLP-1 analogue Victoza (liraglutide). The product is intended

The injection is indicated for reversal of the effects of nondepolarizing neuromuscular blocking agents (NMBA) after surgery. The drug is claimed to be the first approved by the

Solasia is currently completing a Phase I study of darinaparsin in Japan and South Korea to treat patients with relapsed and refractory peripheral T-cell lymphoma (hereinafter "PTCL"). Solasia

The new partnership with Janssen brings to nine the number of pharmaceutical companies around CQDM’s table, increasing the financial leverage that partners generate together. Thanks to CQDM’s unique

This NIH/National Institute of Neurological Disorders and Stroke (NINDS) award will support NIH’s Drug Manufacturing and Formulation Program (DMFP), which is a component of the Blueprint Neurotherapeutics Network

Dipraglurant, a novel small molecule inhibitor of the metabotropic glutamate receptor 5, has shown promise in the treatment of levodopa-induced dyskinesia and dystonia in Parkinson’s disease. Dipraglurant has

OnCore would continue as a subsidiary of Tekmira, and the licensing agreement for NVP018 between NeuroVive and OnCore will remain in force following the merger as the combined

If approved, paliperidone palmitate will be the first and only long-acting atypical antipsychotic that has a dosing schedule of just four times a year. Schizophrenia is a complex

The approval follows an expedited review and positive opinion issued by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) in November 2014. In